There is a lack of data about the effects of Eliquis on pregnant or breastfeeding women.Guidelines suggest avoiding the use of Eliquis in people who are obese (BMI >40kg/m2 or weight of 120kg or more) because there is a lack of research investigating the use of the drug in this population.May interact with several other drugs including ketoconazole, carbamazepine, phenytoin, rifampin, and St John's Wort.May be difficult to confirm if the "one dosage fits all" regimen suits everybody because there is not a commercial blood test available to check the actual effect Eliquis is having on each individual taking it.
May not be suitable for some people including those with artificial heart valves or with active bleeding.The risk is greater in those taking other medications that affect blood clotting (such as NSAIDs or aspirin), with a history of traumatic or repeated spinal procedures or a history of spinal deformity or surgery. There is an increased risk of spinal or epidural hematomas resulting in long-term or permanent paralysis forming in people taking Eliquis who are also undergoing spinal puncture or epidural or spinal anesthesia.Consider coverage with another anticoagulant if Eliquis needs to be stopped for any reason other than significant bleeding or completion of the course of therapy because premature discontinuation has been associated with thrombotic events (the formation of a blood clot within a blood vessel).Also seek urgent medical help with any symptoms of a stroke (such as sudden dizziness, headache or loss of vision difficulty with speech or slurring of your words, one-sided facial drooping) or signs of a blood clot (sudden, severe shortness of breath pain, heat or swelling in a limb). Call 911 if you experience severe or unstoppable bleeding, pink or brown urine, red or black tar-like stools, coughing or vomiting up blood or blood clots (may look like coffee grounds).Gastrointestinal side effects such as constipation, vomiting, diarrhea, or abdominal pain may also occur. Minor bleeding, nausea, anemia, and hemorrhage are the most common side effects.If you are between the ages of 18 and 60, take no other medication or have no other medical conditions, side effects you are more likely to experience include: Available as a generic under the name apixaban.Less likely than warfarin to interact with other drugs or foods however, it does interact with some medicines.Crush one 2.5mg or 5mg tablet (depending on the dosage) and suspend in water, 5% dextrose in water, or apple juice, or mix with apple sauce and administer within four hours. A suspension may be made from the tablets for people who cannot swallow tablets whole.When given to prevent DVTs from forming after hip or knee replacement surgery the dosage is 2.5mg twice a day starting 12 to 24 hours after surgery.For people with at least two of the following: aged at least 80 years, body weight 60kg or lower, serum creatinine at least 1.5 mg/dL, then the dosage is 2.5mg twice daily. The recommended dosage for most people is 5mg twice a day. However, the actual risk of major bleeding is low. An antidote was approved in 2018, called andexanet alfa.Eliquis is also used in the treatment of DVT and pulmonary embolism (PE) (where blood clots lodge in the lungs), and to lower the risk of recurrent DVT and PE.Also used to protect against the development of deep vein thrombosis (DVT) (blood clots in the deep veins) following hip or knee replacement surgery.Used to reduce the risk of stroke and blood clot formation in people with nonvalvular Atrial Fibrillation (AF).Eliquis may also be called a direct-acting anticoagulant (DOAC). Eliquis belongs to the class of drugs known as factor Xa inhibitors.Through its action on FXa, apixaban makes blood less likely to clot. Eliquis (apixaban) works by selectively inhibiting (blocking) the effects of factor Xa (FXa), an enzyme that plays a key role in the formation of substances that cause blood clotting.Eliquis is a brand (trade) name for apixaban which may be given to reduce the risk of blood clots.Medically reviewed by Carmen Pope, BPharm.
0 kommentar(er)
